VeriMomeriodictyol hamilelikte güvenli mi?
No harmonised CLP classification or SCCS/CIR safety assessment for eriodictyol was identified (ECHA Annex VI/CIR). Peer‑reviewed literature reports biological activity of the flavanone class and some in vitro estrogenic/ER‑modulating activity for flavonoids (PubMed), so a theoretical mechanism (weak endocrine activity) is possible, but there are no in vivo reproductive toxicity or human teratogenicity data specifically for eriodictyol (PubMed, PubChem). Topical systemic absorption is plausible but expected low for typical cosmetic use given the compound’s flavanone structure and polarity (PubChem).
Related ingredients
Frequently asked questions
- eriodictyol hamilelikte güvenli mi?
- No harmonised CLP classification or SCCS/CIR safety assessment for eriodictyol was identified (ECHA Annex VI/CIR). Peer‑reviewed literature reports biological activity of the flavanone class and some in vitro estrogenic/ER‑modulating activity for flavonoids (PubMed), so a theoretical mechanism (weak endocrine activity) is possible, but there are no in vivo reproductive toxicity or human teratogenicity data specifically for eriodictyol (PubMed, PubChem). Topical systemic absorption is plausible but expected low for typical cosmetic use given the compound’s flavanone structure and polarity (PubChem).
- eriodictyol emzirirken güvenli mi?
- No evidence of reproductive or lactation hazards, no harmonised classification or CIR/SCCS opinion (ECHA Annex VI; CIR). Theoretical endocrine activity based on class/limited in vitro data supports a low mechanistic concern only (PubMed). Systemic exposure after topical application is expected low but measurable, so breastmilk exposure would be low (PubChem; no specific human PK data found).
- eriodictyol bebek cildi için güvenli mi?
- No infant‑specific toxicity data or harmonised flags (ECHA Annex VI/CIR). Mechanistic concern remains theoretical only (flavonoid class in vitro activity) with no in vivo reproductive/developmental data for eriodictyol (PubMed). Dermal exposure concern is elevated for 0–3 yr due to higher skin permeability and surface‑area‑to‑weight ratio; if adult topical exposure is low but measurable (e=1), infant exposure is increased by +1 per guidance (PubChem, PubMed).
- VeriMom eriodictyol nasıl puanlıyor?
- VeriMom eriodictyol'yi EU CosIng, ECHA sınıflandırmaları ve PubMed çalışmalarına göre 87/100 (düşük risk) olarak puanlar.
- Hamilelikte eriodictyol yerine neler kullanılabilir?
- Benzer işlevli ve bilinen riski olmayan alternatifleri içeren listemize bakın.
Her etiketi 2 saniyede kontrol et
VeriMom'u ücretsiz indirin — herhangi bir ürünü tarayın ve hamilelik güvenlik puanını anında görün.
Tıbbi Sorumluluk Reddi
Bu bilgiler yalnızca eğitim amaçlıdır ve tıbbi tavsiye niteliği taşımaz. Güvenlik puanları kamuya açık verilere dayanmaktadır ve tüm riskleri yansıtmayabilir. Hamilelik veya emzirme döneminde herhangi bir ürünü kullanmadan önce her zaman sağlık uzmanınıza danışın.